<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04591522</url>
  </required_header>
  <id_info>
    <org_study_id>Yongping_Chen</org_study_id>
    <nct_id>NCT04591522</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplantation in Cirrhosis</brief_title>
  <acronym>FMT</acronym>
  <official_title>The Study of HIF-1α in Cirrhosis by Fecal Microbiota Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Wenzhou Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with cirrhosis were recruitted and divided into cintrol group and FMT group.&#xD;
      Patients in FMT group were carried by fecal microbiota transplantation, and biochemical&#xD;
      indexes, intestinal flora and intestinal HIF expression were observed before and after FMT&#xD;
      respectively.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blood ammonia</measure>
    <time_frame>Change from baseline blood ammonia at 12 months</time_frame>
    <description>blood ammonia in umol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>alanine aminotransferase</measure>
    <time_frame>Change from baseline alanine aminotransferase at 12 months</time_frame>
    <description>alanine aminotransferase in U/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>aspartate aminotransferase</measure>
    <time_frame>Change from baseline aspartate aminotransferase at 12 months</time_frame>
    <description>aspartate aminotransferase in U/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>gut microbiome</measure>
    <time_frame>Change from baseline gut microbiome at 12 months</time_frame>
    <description>16S RNA sequencing in gut microbiome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>white blood cell</measure>
    <time_frame>Change from baseline white blood cell at 12 months</time_frame>
    <description>white blood cell in /L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hemoglobin</measure>
    <time_frame>Change from baseline hemoglobin at 12 months</time_frame>
    <description>hemoglobin in g/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood platelet</measure>
    <time_frame>Change from baseline blood platelet at 12 months</time_frame>
    <description>blood platelet in/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>albumin</measure>
    <time_frame>Change from baseline albumin at 12 months</time_frame>
    <description>albumin in g/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood glucose</measure>
    <time_frame>Change from baseline blood glucose at 12 months</time_frame>
    <description>blood glucose in mmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>Change from baseline serum creatinine at 12 months</time_frame>
    <description>Serum creatinine in umol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>direct bilirubin</measure>
    <time_frame>Change from baseline direct bilirubin at 12 months</time_frame>
    <description>direct bilirubin in umol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>indirect bilirubin</measure>
    <time_frame>Change from baseline indirect bilirubin at 12 months</time_frame>
    <description>indirect bilirubin in umol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>prothrombin time activity percentage</measure>
    <time_frame>Change from baseline prothrombin time activity percentage at 12 months</time_frame>
    <description>prothrombin time activity percentage in %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>liver stiffness</measure>
    <time_frame>Change from baseline liver stiffness at 12 months</time_frame>
    <description>liver stiffness in Kpa</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of HIF-1α in intestine</measure>
    <time_frame>Change from baseline HIF-1α expression in intestine at 12 months</time_frame>
    <description>Concentration of HIF-1α expression in intestine by western blot</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cirrhosis, Liver</condition>
  <arm_group>
    <arm_group_label>FMT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were carried by fecal microbiota transplantation which described in detail that fecal bacteria are extracted from the faeces of healthy people and poured into the intestines of patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Healthy fecal bacteria liquid</intervention_name>
    <description>Fecal bacteria liquid were obtained from healthy people by a feces processor, and perfused into the patient's intestine.</description>
    <arm_group_label>FMT group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of cirrhotic&#xD;
&#xD;
          -  aged 18-80 years.&#xD;
&#xD;
          -  must be able to cooperate with treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with severe cardiac, pulmonary and renal dysfunction;&#xD;
&#xD;
          -  Patients with severe hypertension and cerebrovascular accidents;&#xD;
&#xD;
          -  Patients with liver cancer or active infection are in the active stage of hepatic&#xD;
             encephalopathy or gastrointestinal bleeding;&#xD;
&#xD;
          -  Prothrombin activity ≤40%, platelet count &lt; 50*10^9/L;&#xD;
&#xD;
          -  Patients with intellectual and language disorders and mental disorders;&#xD;
&#xD;
          -  Probiotics with antibiotic and drug grade were used within 3 months prior to sampling;&#xD;
&#xD;
          -  There are prehepatic or posthepatic portal hypertension reasons;&#xD;
&#xD;
          -  Drug history: anticoagulant therapy, use of antiplatelet drugs, and current use of&#xD;
             beta blockers, statins or interferon (IFN) treatment;&#xD;
&#xD;
          -  Peptic colon examination contraindications, such as intestinal perforation, intestinal&#xD;
             obstruction, etc.&#xD;
&#xD;
          -  Other researchers believe that patients should not be included in the group.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yongping Chen, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Wenzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yongping Chen, Prof</last_name>
    <phone>+8613505777281</phone>
    <email>did@wzhospital.cn</email>
  </overall_contact>
  <results_reference>
    <citation>Sung CM, Lin YF, Chen KF, Ke HM, Huang HY, Gong YN, Tsai WS, You JF, Lu MJ, Cheng HT, Lin CY, Kuo CJ, Tsai IJ, Hsieh SY. Predicting Clinical Outcomes of Cirrhosis Patients With Hepatic Encephalopathy From the Fecal Microbiome. Cell Mol Gastroenterol Hepatol. 2019;8(2):301-318.e2. doi: 10.1016/j.jcmgh.2019.04.008. Epub 2019 Apr 18.</citation>
    <PMID>31004827</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>October 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 11, 2020</last_update_submitted>
  <last_update_submitted_qc>October 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cirrhosis；fecal Microbiota Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

